Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ipsen SA
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.
Truvian Sciences will use the proceeds to fund regulatory submission for its POC testing system in Europe and the US with hopes to bring to retailers, pharmacies, health systems in 2022.
France’s Ipsen reports a solid financial performance in 2020 but is cautious about guidance for 2021, as the mid-sized pharmaceutical company’s next rare disease candidate nears the market and it looks for early-stage assets to add to its pipeline.
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Clementia Pharmaceuticals, Inc.
- Ipsen Bioscience, Inc.
- Tercica, Inc.
- Syntaxin Ltd.
- OctreoPharm Sciences GmbH
- Octagen Corporation